Better Health for All

CVRx's Barostim System, its sole product, is FDA-approved for heart failure and resistant hypertension, and is the first FDA-approved neuromodulation technology for heart failure symptoms.

Clinical data shows significant health benefits, including an 84-86% reduction in all-cause, cardiovascular, and heart-failure hospital visits, and a 34% relative reduction in all-cause death or the use of LVAD or heart transplant over 4+ years. The product also simulates reductions in MI (19%), stroke (35%), heart failure (12%), and ESRD (23%) over a lifetime, adding 1.66 life-years and 2.17 quality-adjusted life years. The company has no revenue from products with negative health impacts. The BeAT-HF trial reported a 96.9% freedom from major adverse events and a 92.5% overall complication-free rate over 41.9 months, with 30-day system/procedure complications at 6.3% and 30-day to 6-month complications at 1.3%. CVRx provides a list of potential operative and post-operative risks for the Barostim System, including death, and states that patients may receive MRI only when all MR Conditional safety parameters are met. The company's R&D expenses were $11.1 million for the year ended December 31, 2024, against total revenue of $51.3 million, representing 21.6% of revenue. CVRx has conducted randomized, controlled clinical trials, including the 322-patient Rheos Hypertension Trial and a 146-patient trial for heart failure, and the 2,500-patient BENEFIT-HF trial is a randomized study supported by CMS Category B IDE coverage. The company states that only trained physicians may use the system and prescribing physicians should be experienced in the diagnosis and treatment of heart failure and familiar with the system's use.

Fair Money & Economic Opportunity

CVRx, Inc. is a medical device company focused on developing, manufacturing, and commercializing neuromodulation solutions for cardiovascular diseases.

The provided articles detail the company's financial performance, operating metrics, and regulatory actions related to its medical device, the Barostim System. There is no evidence in the articles that CVRx, Inc. offers any lending, deposit, or other financial services to consumers or businesses. Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable, as the company's core business lies outside the financial services sector.

Kind to Animals

CVRx conducts pre-clinical animal studies for its medical devices, which are a required part of safety testing under Good Laboratory Practice (GLP) guidelines for regulatory approvals (CE mark, FDA IDE).

The company's policy involves conducting animal studies, including selecting animal models and coordinating results, for safety evaluations. These studies include ovine (sheep) models for chronic safety evaluations. Specifically, seven male crossbred sheep were used in chronic studies (12 and 24-week survival groups), and three ovine animals were used for 180-day chronic testing. While CVRx also employs *in vitro* (benchtop) testing using electrochemical techniques and optical microscopy, these non-animal methods appear to cover early-stage assessments, with animal studies remaining critical for complex, long-term safety endpoints. The Institutional Animal Care and Use Committee (IACUC) review board at American Preclinical Services, LLC approved the procedures for the ovine studies.

No War, No Weapons

CVRx, Inc. is a medical device company focused on cardiovascular diseases, with no evidence of involvement in arms or defense-related activities.

For the year ended December 31, 2024, the company conducted a reasonable country of origin inquiry for 3TG Minerals but was unable to obtain documentation from some suppliers regarding the presence or origin of these minerals. Consequently, the company cannot rule out the possibility that products contained 3TG Minerals originating in the Democratic Republic of the Congo or an adjoining country, indicating that less than 10% of its supply chain is verified conflict-free. The company asked its suppliers to provide answers to a Supply Chain Questionnaire adapted from the Responsible Minerals Initiative's Conflict Minerals Reporting Template, but its inability to obtain documentation from some suppliers suggests that humanitarian procurement standards are rarely enforced.

Planet-Friendly Business

No specific, quantitative data points related to CVRx's planet-friendly business practices, such as carbon emissions, renewable energy use, water consumption, or waste diversion rates, were found in the provided articles.

The articles focused on financial health and aggregated ESG risk ratings without offering detailed environmental performance metrics.

Respect for Cultures & Communities

No specific, concrete data points were found in the provided articles regarding CVRx, Inc.'s respect for cultures and communities.

The articles explicitly state a lack of information on community engagement, cultural impact assessments, or other relevant social responsibility initiatives.

Safe & Smart Tech

CVRx's privacy notice states that users have rights to access, update, delete, and restrict data processing, and to object to processing for marketing purposes.

The company also indicates that data is retained only as long as necessary for the purpose of collection. Furthermore, CVRx asserts compliance with applicable laws, including those related to medical devices, pharmacovigilance, and data protection.